Sildenafil citrate tablets IP 100 mg: PCD franchise and third-party manufacturing
Laafon Galaxy Pharmaceuticals offers sildenafil citrate tablets IP 100 mg on two routes: a sildenafil PCD franchise for the L-Force-100 brand, and third-party manufacturing of the same tablet under your brand name. Production for both routes takes place at a partner third-party WHO-GMP certified unit; Laafon Galaxy is the marketer and coordinates supply. Sildenafil citrate is a Schedule H drug[1] with no NPPA ceiling price.[2][3] Indian advertising law sharply limits how it may be promoted (see the compliance section below).[4]
- MoleculeSildenafil citrate IP, 100 mg
- ScheduleH (Rx only)
- Price controlNon-scheduled
- Made atPartner WHO-GMP unit
- RoutesPCD · contract manufacturing
Products we currently supply under this molecule
L-Force-100: Sildenafil Citrate Tablets IP 100 mg
- Composition
- Each film-coated tablet: Sildenafil Citrate IP eq. to Sildenafil 100 mg
- Pack
- 1 × 4 blister in a mono carton; 10 mono cartons per shipper (10 × 1 × 4)
- MRP
- ₹128.00 per strip of 4
- Strength
- 100 mg only
- Status
- Rx · Schedule H[1]
- Manufactured at
- Partner third-party WHO-GMP certified unit, named on the label
For indications, dosing, contraindications and interactions, see the L-Force-100 and sildenafil citrate tablets IP 100 mg clinical monograph. This trade page deliberately makes no therapeutic claims.
Sildenafil PCD franchise vs third-party manufacturing
| Point | PCD franchise (L-Force-100) | Third-party manufacturing (your brand) |
|---|---|---|
| Brand on the pack | L-Force-100, owned by Laafon Galaxy | Your brand name. Run a trademark search before you print artwork |
| Manufacturer on the label | The partner third-party WHO-GMP certified unit | The partner third-party WHO-GMP certified unit, which must hold product permission for sildenafil citrate tablets |
| Licence you need to sell | A wholesale drug licence in Form 20B, the form for drugs outside Schedules C, C(1) and X[1] | The same Form 20B licence to stock and distribute,[1] plus your marketer details on the label |
| Pack and MRP | Fixed: 10 × 1 × 4, MRP ₹128.00 per strip | You choose pack and MRP. As a non-scheduled formulation, later MRP increases are capped at 10% in 12 months[3] |
| Artwork | Ready, approved artwork | Yours to supply, compliant with Drugs Rules labelling, including the Schedule H caution |
| Commercial terms | See PCD franchise terms | See third-party manufacturing terms |
| Best fit | A distributor who wants an established pack to sell in an assigned area | A marketer building its own brand portfolio |
Scroll sideways to see both columns.
Want a manufacturing licence in your name without owning a plant? A loan licence in Form 25A, granted under Rule 69A, is a third route.[1] See pharma loan licence consulting.
Plan for a crowded market. In October 2026, 1mg listed 182 substitutes for a single sildenafil 50 mg brand.[6] The molecule will not set you apart. Pack, price, availability and service to retailers will, so cost a sildenafil launch on that basis.
Compliance limits for selling sildenafil in India
Advertising: the hard limit
Section 3(b) of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 bans any advertisement suggesting that a drug maintains or improves capacity for sexual pleasure. Its Schedule also names “sexual impotence”. On a first conviction the penalty is up to six months’ imprisonment, a fine, or both; on a later conviction, up to one year.[4] The Act exempts material sent confidentially to registered medical practitioners (section 14).[4]
Claims on packs and literature
Under Rule 106 and Schedule J of the Drugs Rules, 1945, a drug may not claim to cure “sexual impotence, premature ejaculation and spermatorrhoea”.[1] The UCPMP 2024 bars the word “safe” without qualification and any “no side effects” claim, and requires claims to rest on current evidence.[5] Keep visual aids within the approved prescribing information.
Schedule H distribution
Sildenafil citrate is entry 453 of Schedule H.[1] Supply licensed retailers, hospitals and practitioners only. A retailer may sell to a patient only against a registered medical practitioner’s prescription.
Do not
- Run public social-media posts, ads or WhatsApp broadcasts promoting sildenafil for sexual performance.
- Use “safe”, “no side effects”, “guaranteed results” or performance language on packs, visual aids or price lists.
- Sell to unlicensed resellers or online sellers who do not take a prescription.
Distributor readiness check
Tick what you already have in place. Nothing you tick is stored or sent anywhere.
0 of 7 in place
Start with the drug licence. Stock can be supplied only to a licensed buyer, so this comes first.
Sildenafil third-party manufacturing: what we need from you
From you
- Brand name, with a trademark search done
- Strength and pack style. L-Force-100 is 100 mg; ask before planning other strengths, because they depend on the partner unit’s product permission
- Order quantity and delivery schedule
- Approved artwork with the marketer’s name and address
What to ask for on every batch
- The manufacturer’s name and licence number on the label
- A certificate of analysis against the Indian Pharmacopoeia standard the label claims
- Batch number, manufacturing and expiry dates on strip and carton
- The Schedule H caution on the strip
Get sildenafil trade terms
Send us your drug licence details, the area you cover, and whether you want L-Force-100 or your brand.
Trade questions on sildenafil
Schedule H. Sildenafil citrate is entry 453 of Schedule H in CDSCO’s consolidated Drugs and Cosmetics Rules, 1945, and it does not appear in Schedule H1 or Schedule X. Retail sale needs a registered medical practitioner’s prescription, but there is no H1 sale register.
No. Sildenafil is not in the National List of Essential Medicines 2022, so its tablets are non-scheduled formulations under DPCO 2013. The marketer sets the MRP, and paragraph 20 caps any increase at 10% over the preceding 12 months.
Not to the public with any suggestion of improving sexual capacity or treating impotence. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 prohibits such advertisements. A first conviction carries up to six months’ imprisonment, a fine, or both. Material sent confidentially to registered medical practitioners is exempt.
A wholesale licence in Form 20B. Under Rule 61(1) of the Drugs Rules, 1945, this is the form for selling by wholesale drugs other than those in Schedules C, C(1) and X, and sildenafil tablets fall in that group. The licence is issued by the State Drugs Controller for the premises.
A partner third-party WHO-GMP certified unit makes it under contract, and Laafon Galaxy Pharmaceuticals markets it. The manufacturer’s name and licence number are printed on every strip and carton. Third-party orders under your brand are arranged through the same partner route.
L-Force-100 comes only in 100 mg. For a third-party order in another strength, ask us first. Whether it can be supplied depends on the partner unit holding product permission for that strength.
Related on Laafon
Who wrote this page
Written by Darshan Singh, co-founder, Laafon Galaxy Pharmaceuticals
M.Sc. Organic Chemistry, D.Pharm. 23+ years in pharmaceutical quality control, quality assurance and drug regulatory affairs.
Published 26 Oct 2026 · Regulatory references checked 26 Oct 2026
References
- Ministry of Health and Family Welfare, Government of India. The Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945 (as amended up to 31 December 2016): Rule 61(1) and Form 20B; Rule 69A and Form 25A; Rule 106; Schedule H, entry 453; Schedule J, entry 47. New Delhi: Central Drugs Standard Control Organisation; 2016. Available from: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf. Accessed October 2026.
- Standing National Committee on Medicines. National List of Essential Medicines (NLEM) 2022: report. New Delhi: Ministry of Health and Family Welfare / ICMR; 2022. Available from: https://icmr.gov.in/icmrobject/custom_data/1720338777_report_nlem_2022_f_website.pdf. Accessed October 2026.
- Department of Pharmaceuticals, Government of India. Drugs (Prices Control) Order, 2013. S.O. 1221(E), dated 15.05.2013, paragraphs 2(zb) and 20. Available from: https://pharma-dept.gov.in/sites/default/files/DPCO2013_0.pdf. Accessed October 2026.
- Government of India. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 (Act 21 of 1954), sections 3, 7 and 14 and the Schedule. India Code. Available from: https://www.indiacode.nic.in/indiacode/bitstream/123456789/1412/1/A1954-21.pdf. Accessed October 2026.
- Department of Pharmaceuticals, Government of India. Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, clauses 2.1–2.4. 12 March 2024. Available from: https://www.pharma-dept.gov.in/sites/default/files/UCPMP%202024%20for%20website_0.pdf. Accessed October 2026.
- Tata 1mg. Substitutes for Sidegra 50 Tablet (sildenafil 50 mg) [marketplace listing; secondary source]. Available from: https://mars.1mg.com/drugs-substitutes/sidegra-50-tablet-668610. Accessed October 2026.
Disclaimer. This page is trade information for licensed pharmaceutical distributors and marketing companies. It is not medical advice, legal advice, or an offer to sell to the public. Sildenafil is a prescription medicine. Licence forms, schedules, price rules and advertising law change by notification, so confirm current requirements with your State Drugs Controller before you act. Commercial terms are subject to a written agreement.